View in EDS

Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.

Saved in:
Bibliographic Details
Title: Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Authors: Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Harrison SJ; Peter MacCallum Cancer Centre & Royal Melbourne Hospital Melbourne, Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville, Victoria, 3010, Australia., Bringhen S; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo 0188, Norway.; KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo 0315, Norway., Yong K; Department of Haematology, University College London Hospitals, London WC1N 3BG, UK., Campana F; Sanofi R&D, Cambridge, MA 02142, USA.; Currently, Takeda Pharmaceuticals, Cambridge, MA 02142, USA., Le-Guennec S; Sanofi R&D, Vitry-sur-Seine 94400, France., Macé S; Sanofi R&D, Vitry-sur-Seine 94400, France., Dimopoulos MA; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens 157 72, Greece.
Source: Future oncology (London, England) [Future Oncol] 2021 Dec; Vol. 17 (34), pp. 4797-4812. Date of Electronic Publication: 2021 Sep 15.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34521277
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.<br /><searchLink fieldCode="AU" term="%22Harrison+SJ%22">Harrison SJ</searchLink>; Peter MacCallum Cancer Centre & Royal Melbourne Hospital Melbourne, Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville, Victoria, 3010, Australia.<br /><searchLink fieldCode="AU" term="%22Bringhen+S%22">Bringhen S</searchLink>; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy.<br /><searchLink fieldCode="AU" term="%22Schjesvold+F%22">Schjesvold F</searchLink>; Oslo Myeloma Center, Oslo University Hospital, Oslo 0188, Norway.; KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo 0315, Norway.<br /><searchLink fieldCode="AU" term="%22Yong+K%22">Yong K</searchLink>; Department of Haematology, University College London Hospitals, London WC1N 3BG, UK.<br /><searchLink fieldCode="AU" term="%22Campana+F%22">Campana F</searchLink>; Sanofi R&D, Cambridge, MA 02142, USA.; Currently, Takeda Pharmaceuticals, Cambridge, MA 02142, USA.<br /><searchLink fieldCode="AU" term="%22Le-Guennec+S%22">Le-Guennec S</searchLink>; Sanofi R&D, Vitry-sur-Seine 94400, France.<br /><searchLink fieldCode="AU" term="%22Macé+S%22">Macé S</searchLink>; Sanofi R&D, Vitry-sur-Seine 94400, France.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens 157 72, Greece.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2021 Dec; Vol. 17 (34), pp. 4797-4812. <i>Date of Electronic Publication: </i>2021 Sep 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34521277
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/fon-2021-0568
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4797
    Titles:
      – TitleFull: Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Harrison SJ
      – PersonEntity:
          Name:
            NameFull: Bringhen S
      – PersonEntity:
          Name:
            NameFull: Schjesvold F
      – PersonEntity:
          Name:
            NameFull: Yong K
      – PersonEntity:
          Name:
            NameFull: Campana F
      – PersonEntity:
          Name:
            NameFull: Le-Guennec S
      – PersonEntity:
          Name:
            NameFull: Macé S
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 34
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1